

## **Analytical treatment interruption: detection of an increase in the latent, inducible HIV-1 reservoir more than a decade after viral resuppression**

Cynthia Lungu<sup>1</sup>, Tanvir Hossain<sup>1</sup>, Henrieke A.B. Prins<sup>2,3</sup>, Kathryn S. Hensley<sup>3</sup>, Raquel Crespo<sup>1</sup>, Casper Rokx<sup>2,3</sup>, Shringar Rao<sup>1</sup>, Jeroen J. A. van Kampen<sup>4</sup>, David A.M.C. van de Vijver<sup>4</sup>, Thibault Mesplède<sup>4</sup>, Peter D. Katsikis<sup>5</sup>, Yvonne M. Mueller<sup>5</sup>, Rob A. Gruters<sup>4</sup>, Tokameh Mahmoudi<sup>1,6,7</sup>.

### **Affiliations**

1 Department of Biochemistry, Erasmus University Medical Center, Rotterdam, Netherlands

2 Department of Internal Medicine, Section Infectious Diseases, Erasmus University Medical Center, Rotterdam, Netherlands

3 Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, Netherlands

4 Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

5 Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands

6 Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands

7 Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands

**Correspondence to:** [c.lungu@erasmusmc.nl](mailto:c.lungu@erasmusmc.nl) (C. Lungu) and [t.mahmoudi@erasmusmc.nl](mailto:t.mahmoudi@erasmusmc.nl) (T. Mahmoudi)

### **Abstract**

Analytical treatment interruption (ATI) studies are increasingly being performed to evaluate the efficacy of putative strategies towards HIV-1 reservoir elimination or antiretroviral therapy (ART)-free viral control. A limited number of studies have evaluated the impact of ATI on the HIV-1 reservoir in individuals on suppressive ART. Available data suggests that ATIs have transient impact on the HIV-1 reservoir, mostly measured by levels of total or integrated HIV-1 DNA, in peripheral blood cells prior to ATI and shortly after ART-mediated viral resuppression. The long-term impact of intervention ATI studies on the latent, inducible HIV-1 reservoir remains uncertain. We report the first clinical study demonstrating an increase in the latent, inducible HIV-1 reservoir, measured by expression of *tat/rev* multiply spliced RNA, in nine individuals, despite more than a decade of re-suppressive ART, after undergoing an immune intervention ATI conducted in 2006-2009. Our findings challenge the status quo on ATI risk of viral reservoir reseeding and the long-term outcomes thereof.

## Main

### Introduction

A reservoir of immune cells harboring replication-competent HIV-1, established early during infection (within 3 to 6 days)<sup>1</sup>, persists in the body despite suppressive antiretroviral therapy (ART) and presents a major hurdle to developing a cure for HIV-1 infection. Although raising several debatable ethical concerns<sup>2-4</sup>, analytical treatment interruption (ATI) studies are increasingly being used to assess the efficacy of novel therapeutic strategies designed to target the viral reservoir and/or control HIV-1 in absence of ART<sup>5-7</sup>. Findings from past and recent studies indicate that HIV-1 viremia during ATI may be associated with long-term adverse clinical events, clearly warranting vigilant follow-up of ATI study participants<sup>8-10</sup>. One particular area of concern is the heightened risk of HIV-1 reservoir reseeding during ATI. Recent studies have reported viral reservoir diversity and dynamics shortly after ATI upon intervention, during ATI, but not after viral re-suppression<sup>11-15</sup>. A few studies have assessed the impact of ATI on the viral reservoir, mostly at the level of total or integrated HIV-1 DNA, and after only a limited time following ART-mediated re-suppression (ranging from 3 months to two years)<sup>16-20</sup>, which provide insufficient insight with regards to the long-term outcomes of ATI on the stable, persistent viral reservoir. Here we examined the long-term impact of intervention ATIs by assessing different molecular compartments of the HIV-1 reservoir using peripheral blood samples, collected 15 years apart, from nine individuals who participated in an autologous dendritic cell (DC)-based immunotherapy ATI trial followed by more than 10 years of ART resuppression.

### Results

#### Cohort description

Between April 8, 2021 and June 6, 2021, we recruited nine chronically treated individuals with HIV-1 subtype B who interrupted ART during a non-randomized, phase I/IIa autologous DC-based immunotherapy trial conducted in 2006 (International Clinical Trial Registry Platform: Netherlands trial registry No. NTR2198)<sup>21</sup> (**Fig. 1a**, Extended Data **Table 1**). All participants were stably suppressed with undetectable plasma HIV RNA (<50 HIV-1 RNA copies/mL) for a median of 4.8 (IQR: 4.6-5) years, with CD4+ T cell counts >500 prior to enrollment into the trial. Although the DC vaccine was shown to be safe and well-tolerated<sup>21</sup>, the elicited immune responses were not sufficient to control viral replication off ART as all participants experienced viral rebound (>1000 HIV-1 RNA copies/mL) within two to eight weeks after ATI<sup>21</sup>. The participants included in this study remained off ART for a median duration of 50 weeks (interquartile range (IQR): 28.5 - 96), with prolonged viremia, until resuming ART (**Fig. 1b**), which was in accordance with protocol-defined criteria based on CD4+ T-cell count or necessity of re-treatment according to earlier guidelines<sup>21</sup>. From a retrospective analysis of routine clinical data, we observed that all participants achieved viral re-suppression (plasma HIV-RNA <50 copies/mL) within 18 months after resuming ART. Plasma antiretroviral drug levels measured one month after resuming ART were within therapeutic range. Approximately two years after resuming ART, while CD4+ T cell counts had increased to levels that were comparable to baseline, the CD4/CD8 ratio was significantly lower relative to baseline (pre vaccination, T0) (**Extended Data Fig. 1**). However, at enrollment into the current study, the participants had been virally suppressed for >10 years and the mean CD4+ T cell counts and CD4/CD8 ratio were comparable to baseline levels

before vaccination and ATI (T0) (**Extended Data Fig. 1**). Viral blips (50-400 HIV-1 RNA copies/mL) after viral re-suppression were detected in three participants with no clear clinical explanation (**see note, Extended Data Table 1**). There was no indication of ART failure, non-adherence, or potential reservoir-targeting medication administered over the years post ATI.

### **Transient changes in HIV-1 DNA during ATI**

We assessed HIV-1 persistence at different molecular levels using peripheral blood samples collected at various time points during the DC-TRN trial phase; Baseline (T0, prior to DC vaccination); Pre ATI (T1, one week after the 2<sup>nd</sup> DC vaccination; and T2, one week after the 4<sup>th</sup> DC vaccination); Early ATI (T3, four weeks after ATI start); Late ATI (T4, >24 weeks after ATI start, the last time point before restart ART); and recently collected samples Post ATI (T6, >10 years on stable ART) (**Fig. 1a**). Firstly, we used the intact proviral DNA assay (IPDA)<sup>22</sup>, to analyze the dynamics of intact and defective proviral DNA in response to vaccination and ATI. The DC vaccination did not lead to significant changes in the levels of total proviral DNA per  $1 \times 10^6$  CD4<sup>+</sup> T cells (T2 relative to T0) (**Fig. 1c**). Before ATI (T0 to T2), the proportions of intact proviral DNA increased in two participants, and decreased in four participants (**Extended Data Fig. 2**). Given this apparent variation at T2 we assessed the relationship between intact proviral DNA and time to viral rebound (TVR) to >1000 c/mL. The levels and proportion of intact proviral DNA at T0 trended negatively with TVR, although not significant, given the small numbers and low frequency of intact HIV DNA. Total HIV DNA strongly associated with TVR ( $r = -0.94$ ,  $P = 0.017$ ) (**Extended Data Fig. 3a-c**). In contrast, one week after the last vaccination (T2), the proportion of intact proviral DNA trended significantly with TVR ( $r = -0.8264$ ,  $P = 0.0158$ ) (**Extended Data Fig. 3d-f**). During ATI, as expected, the levels of intact proviral DNA increased (T3 and T4), concomitant with rebounding plasma viremia (**Fig. 1c and d, Extended Data Fig. 2**). At T6, after >10 years of suppressive ART, the levels of total, defective (3' Del/Hypermutated or 5' Del), and intact proviral DNA were overall comparable to pre-ATI (T0, pre vaccination) and/or T2 (post vaccination) (**Fig. 1c and d**). Although, comparing T2 and T6, there was a clear upward trend in the levels and proportion of intact proviral DNA in four participants (**Fig. 1c and Extended Data Fig. 2**).

### **The frequency of gagpol viral RNA<sup>+</sup> cells after a decade of re-suppressive ART is comparable to Pre-ATI**

Intact proviral DNA assessment by IPDA does not indicate the capacity of proviruses to transcribe HIV-1 RNA. Therefore, we used a single cell approach, fluorescent in-situ hybridization coupled with flow cytometry (FISH-flow)<sup>23</sup>, to determine the frequency of CD4<sup>+</sup> T cells expressing unspliced HIV-1 gagpol viral RNA (vRNA) after *ex vivo* treatment with PMA/ionomycin. Due to the limited availability of clinical samples at T0, we were unable to assess the transcription-competent viral reservoir before vaccination. However, the frequency of gagpol vRNA<sup>+</sup> cells per  $1 \times 10^6$  CD4<sup>+</sup> T cells did not differ significantly between the timepoints T1 (median 17.85, IQR: 12.84 - 62.60) and T2 (median 24.11, IQR: 12.05 - 51.34). In fact, the stability of this viral reservoir compartment was remarkable, with the frequency of gagpol vRNA<sup>+</sup> cells before ATI comparable to T6, >10 years post ATI, on stable ART (median 17.6, IQR 12.32 – 43.62) (**Fig. 2a**). As viral translation inhibition has also been implicated to contribute to viral persistence<sup>24,25</sup>, we assessed the frequency of cells simultaneously expressing gagpol vRNA and Gag p24<sup>+</sup> protein (herein referred to as the translation-competent viral reservoir). Across all timepoints, the frequency of translation-competent reservoir cells was low to below detection limit, consistent with values

reported in literature <sup>23,25</sup>. Despite this, the trends in the dynamics of the Gag protein translation-competent reservoir were similar to that of the gagpol transcription-competent reservoir (**Fig. 2b**).

### **Sustained increase in the frequency of cells expressing multiply spliced RNA**

Our group has recently developed a viral reservoir assay termed SQuHIVLa; Specific Quantification of inducible HIV-1 reservoir by LAMP, which leverages reverse transcription loop-mediated isothermal amplification (RT-LAMP) performed in a single reaction, to exclusively detect *tat/rev* multiply spliced (ms)RNA<sup>26</sup>. The frequency of CD4+ T cells expressing *tat/rev* msRNA, which in part reflects viral expression from intact viruses, is more likely to reflect virion production than unspliced gagpol vRNA and may therefore serve as a biomarker of the replication-competent viral reservoir <sup>27</sup>. Using SQuHIVLa we found that the median frequency of CD4+ T cells spontaneously expressing *tat/rev* msRNA at T1 (median 16.32, IQR: 13.23 -19.66) was comparable to T2 (median 19.31, IQR: 15.89 - 21.71). However, the significantly lower frequencies observed in 8/9 participants at T6, on stable ART (median 8.01, IQR: 3.84 -10.38) (**Fig. 2c**), suggests that more cells were spontaneously expressing *tat/rev* msRNA during the vaccination phase, possibly due to immune activation. The median frequency of CD4+ T cells spontaneously expressing *tat/rev* msRNA after DC vaccination trended negatively with time to detectable plasma HIV-1 RNA >50 copies/mL (**Fig. 2d**) and TVR to >1000 copies/mL (**Extended Data Fig. 4a**), the latter not statistically significant given the small sample size and limited variation in TVR to >1000 copies/mL, which was based on weekly plasma HIV-1 RNA measurements. After *ex vivo* treatment with PMA/ionomycin, we observed an increase in the total frequency of CD4+ T cells expressing *tat/rev* msRNA between the Pre ATI (T1 and T2) and Post ATI (T6) timepoints (**Fig. 2e**). Similar results were obtained using a 1-step *tat/rev* induced limiting dilution assay (1-step TILDA), as an alternative method to quantify cells expressing *tat/rev* msRNA, and the two assays positively correlate (**Extended Data Fig. 4 b, c**). Next, we assessed the frequency of cells that could be induced to express *tat/rev* msRNA after PMA/ionomycin treatment (i.e., the difference between the frequency of cells expressing *tat/rev* msRNA spontaneously and after *ex-vivo* stimulation, hereafter referred to as the latent, inducible viral reservoir). Markedly, this viral reservoir compartment was significantly higher at T6 relative to T1 and T2 (P=0.0102 and P=0.0030, respectively) (**Fig. 2f**), indicating an expansion of this viral reservoir compartment.

### **Discussion**

This study provides clear insights, which invite pause and further consideration for future combination ATI trials towards HIV-1 cure; which measures of persistent HIV-1 reservoirs are clinically meaningful and what virologic assays are most appropriate to guide and assess ATI risk? It is plausible that the DC vaccination induced latency reversal *in vivo*, determined by levels of spontaneous *tat/rev* msRNA expression, which significantly trended with time to viral rebound. This finding further confirms *tat/rev* msRNA expression as an attractive biomarker to incorporate into HIV-1 cure-focused trials. Earlier studies by Fischer et al. similarly demonstrated *tat/rev* msRNA expression concomitantly occurring with the re-emergence of PBMC-associated HIV-1 particles (cellular viral rebound) after two weeks of structured ART interruption, which was predicted by during-therapy levels of *nef* msRNA transcripts in PBMCs <sup>28</sup>. More recently, De Scheerder et al., showed an increase in *tat/rev* RNA transcripts, amongst elevated expression of restriction factors (SLFN11 and APOBEC3G), after ATI prior to viral rebound, indicating the use of these restriction factors and *tat/rev* RNA as potential biomarkers for imminent viral

rebound<sup>16</sup>. Importantly, despite the fact that the participants in this study underwent unconventionally long ATI with less stringent monitoring and ART restart criteria, we report no significant impact on the HIV-1 reservoir at the level of proviral DNA and gagpol viral RNA expression, consistent with reports from several recent, well monitored, short-term ATI interventions<sup>16-19,29-32</sup>. After more than a decade of suppressive ART post ATI, defective and intact proviral DNA were overall comparable to baseline prior to ATI, although, a clear upward trend in the levels and proportion of intact proviral DNA was observed in four/nine participants. Cell associated HIV-1 gagpol vRNA expression at single cell level was remarkably stable across time points pre and post ATI, whereas the translation-competent viral reservoir, defined by gagpol viral RNA and Gag p24 protein co-expression, was more dynamic. Collectively, the available data, including ours, suggest that viral reservoir expansion during ATI is transient and supports the notion that sustained viral reservoir increase after ATI is not a concern, at least at the level of proviral DNA and cellular reservoirs expressing gagpol viral RNA. However, we also demonstrate a significant increase in the frequency of cells inducibly expressing tat/rev msRNA in all nine study participants, which challenges the status quo and demands further attention.

To explain our findings, we consider several factors. Indeed, the DC vaccination induced enhanced immune responses, which sustained throughout the ATI phase<sup>33</sup>, but were not sufficient to control viral replication. Consequently, persistent immune activation during ATI would increase the number of target cells and drive clonal expansion. Moreover, while establishment of the latent reservoir occurs very early during primary infection<sup>1</sup>, the prolonged duration of ATI in this trial, in an ART era where substantial levels of prolonged viremia and CD4 T-cell declines were more acceptable in routine care, could have likely contributed to continuous viral reservoir reseeding of the latent, replication-competent reservoir during untreated HIV-1 infection<sup>34-36</sup>. In addition, the discrepant outcomes on viral expression may be attributed to an altered proviral landscape and/or shifts in the replication-competent viral reservoir. In fact, transcription-competence determined by gagpol vRNA expression is shown to be a less proximate surrogate marker for replication-competence compared to tat/rev msRNA-expression<sup>27,37</sup> and the two viral markers poorly correlated with each other (**Extended Data Fig. 4d and e**). Moreover, recent work has demonstrated that defective proviruses can produce defective vRNA and proteins, which do not yield competent virions, but may drive changes in the proviral landscape<sup>38-40</sup>. Notably, the levels of intact HIV DNA at T6 associated more with the frequency of tat/rev msRNA<sup>+</sup> cells and not with gagpol vRNA<sup>+</sup> cells (**Extended Data Fig. 4f-h**). An important limitation of our study is the absence of a control group in the DC-TRN trial. Thus, we cannot definitively exclude increases in the latent, inducible reservoir following a normal clinical course or consequent to aging on suppressive ART. However, studies in individuals on long-term suppressive ART have revealed essentially stable defective proviral levels whereas intact proviral DNA gradually declines in majority of individuals<sup>41,42</sup>, although the frequency of cells with inducible tat/rev msRNA were not investigated in these studies. We postulate that the inability of cytotoxic T lymphocyte (CTL) clearance together with the existence of intact but transcriptionally silent proviruses and clonal expansion is a plausible explanation for increases in latent, inducible viral reservoir compartment<sup>41</sup>, triggered by the intervention ATI that these participants underwent. The clinical significance of this altered viral reservoir compartment and potential implications for future curative strategies warrants further research

To conclude, the discordant findings accentuate the complexity of assessing persistent viral reservoir dynamics in response to novel therapeutic interventions. Future intervention ATI trials should aim to include a comprehensive assessment of viral and immunological compartments before and during ATI, prior to viral rebound, to identify the most relevant biomarkers and gene signatures that are predictive of viral rebound. In this study, the frequency of intact proviral DNA and cells spontaneously expressing tat/rev mRNA trended negatively with time to viral rebound. It is important to further assess these parameters in combination with immunological and host gene expression profiles in prospective trials to ultimately guide decisions regarding the safety and risk of future intervention ATI trials. Indeed, the noticeable differences in the outcomes of the latent, inducible viral reservoir compartment warrant the need for vigilant monitoring for possible long-term reservoir reseeding consequent to an (immune) intervention, viral rebound post ATI, and after ART-mediated viral re-suppression (short and long-term).

## Materials and Methods

### Ethics statement

Participants of the DCTRN trial provided written informed consent prior to inclusion in accordance with the regulations of the institutional Medical Ethics Committee at Erasmus Medical Center, Rotterdam (MEC-2005-227 and MEC-2012-583). The remaining material from the DCTRN trial was stored in a registered biobank, which was approved by the Erasmus Medical Center Medical Ethics Committee (MEC-2022-0060). The HIV biobank is described at <https://ehcg.nl/en/Our-Projects/HIV-Biobank>.

### Plasma HIV-1 RNA monitoring

Quantification of plasma HIV-1 RNA was performed on three different platforms available at various longitudinal timepoints during DC-immunotherapy, at treatment interruption and on ART. Between 2002 and 2008, quantification was performed using the Roche Amplicor HIV-1 RNA monitor test (version 1.5) (LOQ 50 copies/mL). After 2009 plasma HIV-1 RNA was quantified using the COBAS TaqMan Assay (Roche); LOQ 20 copies/mL. As of 2021, plasma HIV-1 RNA was quantified using the Aptima HIV-1 Quant Dx assay; LOQ 30 copies/mL.

### Clinical sample collection and cell isolations

Cryopreserved PBMCs obtained from large blood draws or leukapheresis material collected from the study participants during the trial phase and post intervention were used for this study. Upon thawing PBMCs, CD4<sup>+</sup> T cells were isolated by negative magnetic selection using the EasySep Human CD4<sup>+</sup> T cell Enrichment kit (StemCell Technologies) according to the manufacturer's instructions. The isolated CD4<sup>+</sup> T cells were either directly used to quantitate HIV-1 DNA/RNA levels or treated with 100 ng/mL phorbol 12-myristate 13-acetate (PMA) and 1 µg/mL ionomycin to enhance viral reactivation.

### Intact Proviral DNA Assay (IPDA)

The levels of intact proviral DNA were assessed using lysed extracts of CD4<sup>+</sup> T cells. Nucleic acid was isolated from at least  $2 \times 10^6$  CD4<sup>+</sup> T cells using the PCI extraction method. Duplex digital PCR (dPCR) was performed on an Absolute Q digital PCR platform (Thermo Fisher Scientific) using primer and probe sets targeting the packaging signal ( $\Psi$ ) and Envelope gene (*Env*), following the manufacturer's instructions and adapted intact proviral DNA assay protocol<sup>22,43,44</sup>. Duplex HIV-1 dPCR reaction mix consisted of 1.8 µL Absolute Q DNA Digital PCR Master Mix 5X (Thermo Fisher Scientific), 1 µL packaging signal ( $\Psi$ ) target FAM-probe (10x), 1 µL *Env* target HEX-probe (10x), 700 ng gDNA, diluted in nuclease-free H<sub>2</sub>O to a final reaction volume of 9 µL. The dark competition probe for APOBEC3G hypermutations in the ENV region was omitted this reaction setup. Measurements of the cellular gene ribonuclease P/MRP subunit p30 (*RPP30*) in a replicate well were used to calculate the frequency of CD4<sup>+</sup> T cells. The duplex *RPP30* dPCR was set up similarly using *RPP30* primer and probe sets and 7 ng gDNA input. The primer and probe sequences used are provided below.

## IPDA primers and probes

	Region	Sequence	Assay
PSI Forward primer	PSI	CAGGACTCGGCTTGCTGAAG	IPDA <sup>22</sup>
PSI Reverse primer	PSI	GCACCCATCTCTCTCCTCTAGC	IPDA <sup>22</sup>
Psi Probe	PSI	/56-FAM/TTTGGCGT/ZEN/ACTCACCAGT/3IABkFQ/	IPDA <sup>44</sup>
Env Forward Primer	Env	AGTGGTGCAGAGAGAAAAAAGAGC	IPDA <sup>22</sup>
Env Reverse Primer	Env	GTCTGGCCTGTACCGTCGC	IPDA <sup>22</sup>
Env Probe	Env	/5HEX/CCTTGGGTT/ZEN/CTTGGGA/3IABkFQ/	IPDA <sup>44</sup>

## FISH-flow

The frequency of cells expressing gagpol viral RNA (vRNA) and p24 protein were assessed using the Primeflow RNA Assay (Thermo Fisher Scientific) following the manufacturer's instructions and as described previously<sup>23,45</sup>. Briefly, CD4+ T cells were isolated from PWHIV donor PBMCs by negative magnetic selection using the EasySep Human CD4+ T cell Enrichment kit (StemCell Technologies) according to the manufacturer's instructions. A minimum of  $20 \times 10^6$  CD4+ T, resuspended at  $1.5 \times 10^6$  cells/mL in RPMI-1640 medium supplemented with 10% FBS, 100 µg/mL penicillin-streptomycin and Raltegravir (3 µM) and rested for at least 4 hours in a humidified incubator at 37°C and 5 % CO<sub>2</sub>. Cells were then treated with 100 ng/mL PMA and 1 µg/mL ionomycin to enhance viral reactivation. Eighteen hours post stimulation, cells were washed, pellets resuspended in PBS, and counted using an automated cell counter (Countess II, Thermo Fisher Scientific). At least  $10 \times 10^6$  cells, with >55% viability, were subjected to the FISH-flow assay. CD4+ T cells were first stained in Fixable Viability dye 780 (Thermo Fisher Scientific) for 20 min at room temperature (1:1000 dPBS) and then fixed and permeabilized using reagents from the Primeflow RNA assay kit according to manufacturer's instructions. After permeabilization, the cells were stained with two p24 antibodies; anti-p24 KC57-FITC (Beckman Coulter, 6604667) and anti-p24 28B7-APC (MediMabs, MM-0289-APC), incubated in the dark for 30 min at room temperature, and an additional 30 minutes at 4 °C. Cells were then washed and resuspended in RNA wash buffer with RNAsin. mRNA was labelled with a set of 40 probe pairs against the GagPol region of vRNA (catalogue number GagPol HIV-1VF10-10884, Thermo Fisher Scientific) diluted 1:5 in the probe diluent provided in the kit. Target mRNA hybridization was carried out for 2 hours at 40°C. Samples were washed to remove excess probes and stored overnight, at 4 °C, in the presence of RNAsin. Signal amplification was then performed by sequential 1.5-hour, 40 °C incubations with the pre-amplification and amplification mix. Amplified mRNA was labelled with fluorescently tagged probes for 1 hour at 40°C. Samples were washed, resuspended in 200-300 µL storage buffer and up to  $5 \times 10^6$  cells were acquired on a BD LSR Fortessa Analyser. Gates were set using stimulated, uninfected CD4+ t cells. Data were analyzed using the FlowJo V10 Software (Treestar).

## Specific Quantitation of Inducible HIV-1 reservoir by LAMP (SQuHIVLa)

The frequency of cells spontaneously and inducibly expressing tat/rev multiply (MS) spliced HIV-1 RNA was assessed using a SQuHIVLa assay according to the protocol described elsewhere<sup>26</sup>. Briefly,  $2 - 5 \times 10^6$  total CD4+T cells were resuspended ( $1.5 \times 10^6$  cells/mL) in culture RPMI-1640 medium supplemented with 10% FBS and 100 µg/mL penicillin-streptomycin, and rested for 6 hours in a humidified incubator at 37 °C and 5 % CO<sub>2</sub>. After incubation, some cells were left untreated and directly used to determine basal viral RNA expression or treated with 100 ng/mL PMA and 1 µg/mL ionomycin for 12 hours to induce viral reactivation. Cells from either condition were washed twice in RPMI 1640 media with 3% FBS, then resuspended in PBS and counted using an automated cell counter (Countess II, Thermo Fisher Scientific). A minimum of  $0.5 \times 10^6$  CD4+ T cells, with > 50



% viability, after PMA/ionomycin treatment were analyzed per SQuHIVLa assay performed on a CFX96 Touch Real-Time PCR Detection System thermocycler (BioRad) as described elsewhere <sup>26</sup>.

### **One-step Tat/rev Induced Limiting Dilution Assay (TILDA)**

The frequency of cells expressing tat/rev multiply spliced (ms) HIV-1 RNA was assessed using a modified TILDA protocol <sup>46</sup> i.e. by direct amplification of tat/rev msRNA using a one-step RT-qPCR approach. Briefly, 2 - 5 x 10<sup>6</sup> CD4+ T cells isolated from PWHIV donor PBMCs were rested and treated with PMA/ionomycin as described for the other inducible reservoir assays. A minimum of 0.5 x 10<sup>6</sup> CD4+ T cells, with >50 % viability, after treatment with PMA/ionomycin were analyzed per assay. CD4+ T cells were added in limiting dilution, ranging from 3 x 10<sup>4</sup> cells - 3 x 10<sup>3</sup> cells (22-24 replicates), to a white 96-well qPCR plate (Biorad) containing 20 µL One-step RT-qPCR reagent mix; 5 µL Luna Probe One-Step RT-qPCR 4X Mix with UDG (No ROX) (New England BioLabs), 0.1 µL *tat* 1.4 forward primer and 0.1 µL *rev* reverse primer (both at 100 µM), 0.8 µL HIV tat/rev probe (5 µM), and 14 µL nuclease free water to a final reaction volume of 25 µL. The primer and probe sequences used, as published <sup>46</sup>. The qPCR plates were sealed, briefly centrifuged at 600 x g for 1 min, and a CFX96 Touch Real-time PCR instrument (Biorad) was used to run the following thermocycling program; Carry over prevention step at 25°C for 30 seconds, reverse transcription at 55°C for 10 minutes, initial denaturation at 95°C for 3 minutes followed by 50 cycles of denaturation at 95°C for 10 seconds and extension at 60 °C for 1 minute. The amplification curves in all positive wells at each dilution manually inspected after each run and the number of positive wells were used to determine the frequency of cells positive for tat/rev msRNA using the maximum likelihood method.

### **Statistics and reproducibility**

Data are presented as median with Inter Quartile Range. Spearman rank correlation coefficients were calculated for non-normally distributed variables. Two-tailed P values were calculated.  $P < 0.05$  was considered statistically significant. For the inducible viral reservoir quantification data below the limit of detection, the arbitrary value of 0.5 cells/million were used to plot the data but were not included in statistical analyses. Likely outlier data points were identified using ROUT(Q=10%) and excluded from statistical analyses. Mixed effects model analyses and Tukey's multiple comparison test were used to compare viral reservoir frequencies across timepoints. Adjusted P values were calculated.  $P < 0.05$  was considered statistically significant. Biological replicates (that is, samples at longitudinal timepoints) were measured in most experiments except for inducible HIV reservoir quantification given the limited availability or quality of clinical material (particularly baseline samples). Technical replicates (that is, repeated measurements of the same sample) were as follows: for intact proviral DNA quantification by dPCR, at least two technical replicates; for FISH-flow, experiments were not technically replicated given the limited clinical material; for SQuHIVLa and 1-step TILDA, at least two independent experiments were performed where clinical material was sufficient. Prism 9 for Mac (GraphPad Software) was used to generate graphs and to perform all statistical tests.

## References

1. Chun, T.W., *et al.* Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**, 8869-8873 (1998).
2. Abdel-Mohsen, M., *et al.* Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine* **26**, 1339-1350 (2020).
3. Garner, S.A., *et al.* Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. *J Virus Erad* **3**, 82-84 (2017).
4. Magalhaes, M., Kuritzkes, D.R. & Eyal, N. The ethical case for placebo control in HIV-cure-related studies with ART interruption. *J Virus Erad* **8**, 100084 (2022).
5. Julg, B., *et al.* Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV* **6**, e259-e268 (2019).
6. Kutzler, M.A. & Jacobson, J.M. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. *Curr Opin HIV AIDS* **3**, 131-135 (2008).
7. Lau, J.S.Y., Smith, M.Z., Lewin, S.R. & McMahon, J.H. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. *AIDS* **33**, 773-791 (2019).
8. Richart, V., *et al.* High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption. *AIDS* **35**, 2463-2468 (2021).
9. Strategies for Management of Antiretroviral Therapy Study, G., *et al.* CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* **355**, 2283-2296 (2006).
10. Imaz, A., *et al.* Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. *Antivir Ther* **18**, 125-130 (2013).
11. Gunst, J.D., *et al.* Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. *Nat Med* (2023).
12. Gaebler, C., *et al.* Prolonged viral suppression with anti-HIV-1 antibody therapy. *Nature* **606**, 368-374 (2022).
13. Gruell, H., *et al.* Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. *Lancet Microbe* **3**, e203-e214 (2022).
14. Cole, B., *et al.* Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption. *Cell Rep* **39**, 110739 (2022).
15. Wedrychowski, A., *et al.* Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. *J Virol* **97**, e0125422 (2023).
16. De Scheerder, M.A., *et al.* Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. *J Antimicrob Chemother* **75**, 1311-1320 (2020).
17. Pappasavvas, E., *et al.* Analytical antiretroviral therapy interruption does not irreversibly change pre-interruption levels of cellular HIV. *AIDS* **32**, 1763-1772 (2018).
18. Scutari, R., *et al.* Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. *Viruses* **13**(2021).
19. Strongin, Z., *et al.* Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. *J Virol* **92**(2018).
20. Montserrat, M., *et al.* Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients. *AIDS* **31**, 1895-1897 (2017).
21. Allard, S.D., *et al.* A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. *Clin Immunol* **142**, 252-268 (2012).
22. Bruner, K.M., *et al.* A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature* **566**, 120-125 (2019).
23. Baxter, A.E., *et al.* Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. *Nat Protoc* **12**, 2029-2049 (2017).
24. Sannier, G., *et al.* Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity. *Cell Rep* **36**, 109643 (2021).
25. Grau-Exposito, J., *et al.* Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. *PLoS Pathog* **15**, e1007991 (2019).
26. Hossain, T., *et al.* SQuHIVLa: A novel assay for Specific Quantification of inducible HIV-1 reservoir by LAMP. *bioRxiv*, 2023.2007.2014.548928 (2023).
27. Zerbato, J.M., *et al.* Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. *EBioMedicine* **65**, 103241 (2021).
28. Fischer, M., *et al.* Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. *J Infect Dis* **190**, 1979-1988 (2004).

29. Clarridge, K.E., *et al.* Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. *PLoS Pathog* **14**, e1006792 (2018).
30. Salantes, D.B., *et al.* HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. *J Clin Invest* **128**, 3102-3115 (2018).
31. Huiting, E.D., *et al.* Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection. *J Infect Dis* **220**, 270-274 (2019).
32. Pannus, P., *et al.* Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. *J Int AIDS Soc* **23**, e25453 (2020).
33. de Goede, A.L., *et al.* DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. *Vaccine* **33**, 2922-2929 (2015).
34. Abrahams, M.R., *et al.* The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. *Sci Transl Med* **11**(2019).
35. Brodin, J., *et al.* Establishment and stability of the latent HIV-1 DNA reservoir. *Elife* **5**(2016).
36. Jones, B.R. & Joy, J.B. Inferring Human Immunodeficiency Virus 1 Proviral Integration Dates With Bayesian Inference. *Mol Biol Evol* **40**(2023).
37. Baxter, A.E., O'Doherty, U. & Kaufmann, D.E. Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. *Retrovirology* **15**, 18 (2018).
38. Pollack, R.A., *et al.* Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. *Cell Host Microbe* **21**, 494-506 e494 (2017).
39. Imamichi, H., *et al.* Defective HIV-1 proviruses produce viral proteins. *Proc Natl Acad Sci U S A* **117**, 3704-3710 (2020).
40. Imamichi, H., *et al.* Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. *Proc Natl Acad Sci U S A* **113**, 8783-8788 (2016).
41. Gandhi, R.T., *et al.* Varied Patterns of Decay of Intact HIV-1 Proviruses Over two Decades of Art. *J Infect Dis* (2023).
42. Peluso, M.J., *et al.* Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5**(2020).
43. van Snippenberg, W., *et al.* Triplex digital PCR assays for the quantification of intact proviral HIV-1 DNA. *Methods* **201**, 41-48 (2022).
44. Sarabia, I., Huang, S.H., Ward, A.R., Jones, R.B. & Bosque, A. The Intact Non-Inducible Latent HIV-1 Reservoir is Established In an In Vitro Primary T(CM) Cell Model of Latency. *J Virol* **95**(2021).
45. Rao, S., *et al.* Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. *Nat Commun* **12**, 2475 (2021).
46. Lungu, C. & Procopio, F.A. TILDA: Tat/Rev Induced Limiting Dilution Assay. *Methods Mol Biol* **2407**, 365-372 (2022).

## Acknowledgements

We express our deepest gratitude to all the study participants for their valuable contribution to the DCTRN trial in 2006-2009 and to the current study, without whom this research would not have been possible. We also thank the internist-infectious disease specialists at Erasmus MC for their assistance in recruiting the study participants. Leukapheresis procedures and sample logistics were greatly supported by Erasmus MC HIV research nurses and clinical laboratory staff.

## Funding


C.L. received funding from the Dutch Aidsfonds (grants P-60602 and P-263); SR received funding from Dutch Aidsfonds (grant P-53302); C.R. received funding from Dutch Aidsfonds (grant P-53601); R.A.G. received funding from Dutch Aidsfonds (grant P-60804) and Horizon Europe (grant 681032); TMa received funding from Health Holland (grants LSHM19100-SGF and EMCLSH19023) and ZonMW (grant 40-44600-98-333) and a Building Synergistic Infrastructure for NL4Cure grant.

### **Author Contributions**


Conceptualization: C.L, and T.Ma; Methodology: C.L., T.H. and T.Ma; Investigation: C.L., T.H., H.A.B.P., K.S.H., and R.C; Data Curation and Formal Analysis: C.L. and T.Ma; Data Visualization: C.L. and T.Ma.; Project Administration: C.L., H.A.B.P., K.S.H. and T.Ma.; Supervision: T.Ma; Material and Funding Acquisition: C.L., S.R., C.R., R.A.G and T.Ma.; Writing – Original draft: C.L.; Writing – Review and Editing: C.L., T.H., H.A.B.P., K.S.H., R.C., C.R., S.R., J.J.A.vK., D.A.M.C.V., T.M., P.D.K., Y.M.M., R.A.G., and T.Ma.

### **Data availability**

All data needed to evaluate the results and conclusions in this article are provided in the main text, Methods section and Extended data section. Additional data related to the study may be requested from the lead contact T. Mahmoudi. Unique biological material, where available, can be obtained upon request.



**Fig. 1. Longitudinal Plasma HIV-1 RNA and proviral reservoir dynamics.** **a)** Schematic overview of the longitudinal study phase during the DCTRN vaccination trial, ATI (pre-Vac to 96 weeks) and after 13 years on suppressive ART. The study timepoints (T0-T4) are indicated using colored upward arrows. Analytical ART interruption (ATI) is shown with a red downward arrow. The period during participants restarted ART is indicated using a dotted horizontal line. After the DCTRN trial, participants were not followed up. T5 is during a routine care visit, and no samples were available for reservoir analyses. T6 is 13 years after resuming ART, participants were included in a follow-up study for a single leukaphereses procedure. **b)** Longitudinal plasma HIV-1 RNA kinetics after ATI. The downward colored arrows mark the time of restart ART. **c)** Changes in levels of total, intact and defective proviral DNA in peripheral CD4+ T cells in response to DC vaccination, ATI and ART (resuppression) (the shaded bars depict the ATI phase). Mixed effects model analyses and Tukey's multiple comparison test were used to compare viral reservoir frequencies across timepoints (Adjusted P values are shown). **d)** Change in proportions of intact to defective HIV-1 DNA.




**Fig. 2. Inducible viral reservoir dynamics after ATI and long-term ART.** **a)** Change in reservoir cells expressing unspliced gagpol viral RNA after *ex vivo* treatment with PMA/ionomycin for 18 hours. **b)** Change in translation-competent reservoir (co-expressing gagpol vRNA and Gag p24 protein). Open symbols depict frequencies below the assay limit of detection (dotted line). **c)** Change in reservoir cells spontaneously expressing tat/rev msRNA (*in vivo* response). **d)** Pearson correlation between cells spontaneously expressing tat/rev msRNA before ATI and time to detectable plasma HIV-1 RNA to >50 copies/mL. **e)** Change in reservoir cells expressing tat/rev msRNA after *ex vivo* treatment with PMA/ionomycin for 12 hours. **f)** Change in reservoir cells inducibly expressing tat/rev msRNA after *ex vivo* treatment with PMA/ionomycin for 12 hours (i.e., Difference between cells with spontaneous tat/rev msRNA expression and after stimulation). Mixed effects model analyses and Tukey's multiple comparison test were used to compare viral reservoir frequencies across timepoints. Adjusted P values are shown.

## Extended Data


**Table 1** Participant clinical characteristics

	<b>Median</b>	<b>IQR</b>	<b>Range</b>
Gender	Male (100%)		
Age at DC Vaccination (T0)	45	41.5 - 53	37 - 56
Age on stable ART post intervention (T6)	60	56.5 - 68	52 - 71
Year of HIV Diagnosis	1997	1994 -1999	1988 -2000
Time between HIV diagnosis and ART initiation (weeks)	32	18.5 - 198.0	2 - 442
Time on ART before vaccination (years)	9.9	7.0 -10.85	3.7 - 11.9
Time undetectable on ART before DC vaccination (years)	4.8	4.6 - 5.0	2.8 - 5.3
Peak plasma HIV RNA pre-ART (log <sub>10</sub> c/mL)	5.01	4.86 -5.12	4.73 - 5.31
Nadir CD4 count	230	155 - 5.12	70 - 290
CD4 count pre-ART initiation	370	325 - 435	300 - 650
CD8 count pre-ART initiation	1850	1360 - 2370	1120 - 2890
CD4/CD8 ratio pre-ART initiation	0.24	0.14 - 0.33	0.12 - 0.38
CD4 count before DC vaccination (T0)	650	575 - 715	510 - 940
CD8 count before DC vaccination (T0)	610	470 - 835	400 - 970
CD4/CD8 ratio baseline (T0)	1.21	0.73 - 1.39	0.53 - 1.48
<b>Analytical ART interruption</b>			
Time to viral rebound >50 c/mL (weeks)	3.0	2.3 - 3.65	2.0 - 6.3
Time to viral rebound >500 c/mL (weeks)	3.3	2.65 - 5.15	2.0 - 6.3
Time to viral rebound >1000 c/mL (weeks)	3.3	2.65 - 5.15	2.0 - 8.3
Time to viral rebound >50000 c/mL (weeks)	6.3	3.15 -20.15	2.0 - 40.0
Lowest CD4 count	250	175 - 285	150 - 290
Peak CD8 count	1370	1195 - 2040	1060 - 4400
last CD4 count before ART resumption (T4)	250	180 - 300	150 - 350
Last CD8 count before ART resumption (T4)	820	685 - 1090	580 - 1650
CD4/CD8 ratio before ART resumption (T4)	0.25	0.20 - 0.39	0.17 - 0.43
Weeks off ART	50	28.5 - 96.0	28 - 116
<b>ART resumption</b>			
Time to viral resuppression <50 c/mL (months)	8.5	4.0 - 16.0	3.0 - 18.0
Time on ART post resumption, early (years);T5	2.3	2.2 - 3.2	2.0 - 3.2
CD4 count (T5)	620	525 - 663	490 - 710
CD8 count (T5)	975	617.5 - 1098	520 - 1510
CD4/CD8 ratio (T5)	0.65	0.62 - 0.92	0.38 - 1.0
Time on ART post resumption, late (years);T6	12.4	11.9 - 13.05	11. - 13.3
Time on ART undetectable (years);T6	10.5	7.8 - 11.5	6.2 - 12.9
CD4 count (T6)	590	490 - 780	430 - 800
CD8 count (T6)	650	520 - 770	460 - 2240
CD4/CD8 ratio (T6)	1.02	0.67 - 1.20	0.30 - 1.42


**Note:** Three participants with viral blips (50-400 c/mL) since viral re-suppression. **H003** – 255 c/mL (Oct 2009), 132 c/mL (April 2010), 59 c/mL (Jan 2014); **H006** (slow to suppress after restarting ART) – 57 c/mL and 228 c/mL (Nov 2013); **H008** (slow to suppress after restarting ART); **H017** – 71 c/mL (Jan 2016).








**Extended Fig. 2 Longitudinal HIV-1 DNA dynamics.** Pie charts of intact and defective HIV-1 DNA (5' Deleted [5'Del] and 3' Deleted/Hypermutated [3'Del/Hyper]) are shown. The proportions of intact and defective DNA are shown as percentages of total HIV DNA copies/million CD4+ T cells. Intact HIV DNA was distinguished from defective HIV DNA using the intact proviral DNA assay (IPDA). N/A = not available.



**Extended Fig. 3 Relationship between proviral DNA and time to viral rebound.** (a-c) Relationship with time to viral rebound assessed at timepoint T0, before vaccination. (c) The frequency (percentage), of intact cells represents the proportion of intact HIV DNA copies to total HIV DNA copies/million CD4+ T cells. Open symbol represent sample not detected and thus not included in the correlation analyses. (d-f) Relationship with time to viral rebound assessed at timepoint T2, one week after the last DC vaccination and ~two weeks prior to ATI. Spearman  $r$  correlations and two-tailed  $P$  values are shown.



**Extended Fig. 4 HIV-1 viral reservoir comparisons before ATI, and post ATI after >10 years of suppressive ART.** **a)** Relationship between time to viral rebound and pre-ATI frequency of cells spontaneously expressing *tat/rev* msRNA at timepoint T2, one week after the last DC vaccination. The frequency shown is a ratio of cells with spontaneous expression of *tat/rev* msRNA to the number total number of cells expressing *tat/rev* msRNA after 12h *ex vivo* stimulation with PMA/ionomycin. Viral reservoir data were generated using a SQuHIVLa assay – ‘Specific Quantification of inducible HIV by LAMP’. **(b)** Pre and post ATI comparison of the frequency of cells expressing *tat/rev* msRNA after 12h *ex vivo* stimulation with PMA/ionomycin. Viral reservoir data were generated using a 1-step TILDA approach. A Wilcoxon signed rank test was used to compare the means of the paired samples and a two-tailed P value is shown. **(c)** Pearson correlation of SQuHIVLa and 1-step TILDA using post ATI timepoint 6 viral reservoir data. Spearman correlations of the induced *tat/rev* msRNA+ reservoir and **(d)** the transcription-competent, gagpol viral RNA+ reservoir; **(e)** the translation-competent, gagpol vRNA+/Gag p24+, reservoir; **(f)** intact proviral reservoir (DNA copies/million CD4+ T cells) and **(g)** frequency of intact HIV DNA copies (ratio of intact to total HIV DNA). **(h)** Spearman correlation of the transcription-competent, gagpol viral RNA+ reservoir and the intact proviral reservoir (DNA copies/million CD4+ T cells).